Aggregator

Anhui Jianghuai Automobile Group Corp. extended its slump after three vehicles from its flagship luxury brand were depicted in a media test with broken brake-pedal supports, prompting the automaker to pledge a redesign of the component and offer a free upgrade to owners.

Key PointsBioNTech now has more than 25 phase 2 and phase 3 oncology trials underway, with 15 phase 3 trials targeted by the end of 2026.

I rounded up the best tea kettles, including electric and stovetop options, from brands like Smeg, Fellow and Cuisinart, after talking to tea experts.

Key PointsBioNTech now has more than 25 phase 2 and phase 3 oncology trials underway, with 15 phase 3 trials targeted by the end of 2026.

Terence Atmane spiked his racket, launched a ball over the grandstand and hurled his racket toward fans at the Shanghai Masters qualifying round in an epic tantrum.

Terence Atmane spiked his racket, launched a ball over the grandstand and hurled his racket toward fans at the Shanghai Masters qualifying round in an epic tantrum.

Today's best bets + Parlay of the Day + Missouri St.-Western Kentucky + Bucs-Cowboys TNF

The NBA and FIBA say they are undeterred in moving forward with the NBA Europe plan after EuroLeague's team owners rejected a merger offer this week.

Viant (DSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

The Trump administration said new changes to Trump Accounts could pave the way for several multimillion-dollar donations.

The U.S. police say a 30-year-old offered the killer advice and cash for supplies at least six months before the rampage in British Columbia that left eight dead.

Experts demand transparency from Russia following reports of a second suspected plague death.

Senate Judiciary Committee Democrats have requested that panel chair, Sen. Chuck Grassley (R-Iowa), apologize to ex-special counsel Jack Smith on behalf of his Republican colleagues following a contentious hearing in September.

Fintel reports that on October 8, 2026, Goldman Sachs upgraded their outlook for Rocket Pharmaceuticals (NASDAQGM:RCKT) (DB:9IP1) from Sell to Neutral. This action follows a prior decision on March 2, 2026, when the firm maintained its Sell rating on the stock.On October 7, 2026,

Fintel reports that on October 8, 2026, Goldman Sachs upgraded their outlook for Rocket Pharmaceuticals (NASDAQGM:RCKT) (DB:9IP1) from Sell to Neutral. This action follows a prior decision on March 2, 2026, when the firm maintained its Sell rating on the stock.On October 7, 2026,

At Founderland, a “Coachella for founders,” entrepreneurs trade the convention hall for a Malibu ranch with access to retailers and investors.